ZIOPHARM Oncology Inc. (NASDAQ: ZIOP): Surviving A Volatility – Stocks Register
Home  »  Finance   »  ZIOPHARM Oncology Inc. (NASDAQ: ZIOP): Surviving A...

ZIOPHARM Oncology Inc. (NASDAQ: ZIOP): Surviving A Volatility

ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) price is hovering lower on Monday, September 13, dropping -4.12% below its previous close.

>> 7 Top Picks for the Post-Pandemic Economy <<

A look at today’s price movement shows that the recent level at last check reads $1.82, with intraday deals fluctuating between $1.81 and $1.94. The company’s 5Y monthly beta was ticking 1.99. Taking into account the 52-week price action we note that the stock hit a 52-week high of $5.95 and 52-week low of $1.26. The stock subtracted -2.67% on its value in the past month.


3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Sponsored


ZIOPHARM Oncology Inc., which has a market valuation of $396.47 million, is expected to release its quarterly earnings report Nov 03, 2021 – Nov 08, 2021. Analysts tracking ZIOP have forecast the quarterly EPS to shrink by -0.13 per share this quarter, while the same analysts predict the annual EPS to hit -$0.44 for the year 2021 and up to -$0.45 for 2022. In this case, analysts estimate an annual EPS growth of -15.80% for the year and -2.30% for the next year.

Revisions to the company’s EPS highlights a short term direction of a stock’s price movement, which in the last 7 days came up with no upward and no downward reviews. On the technical perspective front, indicators give ZIOP a short term outlook of 50% Sell on average. Looking at the stock’s medium term indicators we note that it is averaging as a 100% Sell, while an average of long term indicators are currently assigning the stock as 100% Sell.

The overview shows that ZIOP’s price is at present 0.61% off the SMA20 and -15.64% from the SMA50. The Relative Strength Index (RSI) metric on the 14-day timeframe is pointing at 45.09, with weekly volatility standing at 14.37%. The indicator jumps to 11.69% when calculated based on the past 30 days. ZIOPHARM Oncology Inc. (NASDAQ:ZIOP)’s beta value is holding at 1.97, while the average true range (ATR) indicator is currently reading 0.20. Considering analysts have assigned the stock a price target range of $3.00-$7.50 as the low and high respectively, we find the trailing 12-month average consensus price target to be $4.33. Based on this estimate, we see that today’s price at last check is roughly -71.43% off the estimated low and -328.57% off the forecast high. Investors will no doubt be excited to see the share price fall to $3.25, which is the median consensus price, and at that level ZIOP would be -85.71% from recent price.

Turning out attention to how the ZIOPHARM Oncology Inc. stock has performed in comparison to its peers in the industry, here’s what we find: ZIOP’s stock is -4.12% on the day and -26.61% in the past 12 months. Also, Bristol-Myers Squibb Company (BMY) is currently showing down trend of -0.91% while its price kept floating at 6.53% over the past year. Elsewhere in the market, the S&P 500 Index has stumbled -0.10% in today’s early trading, with the Dow Jones Industrial also seeing a negative session so far with -0.43%.

An analysis of the ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) stock in terms of its daily trading volume indicates that the 3-month average is 3.08 million.

>> 7 Top Picks for the Post-Pandemic Economy <<

Current records show that the company has 214.43M in outstanding shares. The insiders’ percentage holdings are 1.60% of outstanding shares while the percentage share held by institutions stands at 57.50%. But the -27.78% downside, the stock’s price has registered year-to-date as of today’s value, will likely reignite investor interest given the prospect of it rallying even higher.

Leave a Comment

Your email address will not be published. Required fields are marked *

Related Posts

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

100% free. stop anytime no spam

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

100% free. stop anytime no spam